**Supplementary Table 2: Clinical trials of CD39 inhibitors**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **NCT** | **Project title** | **Conditions** | **Interventions** | **Sponsor** | **Phases** |
| [NCT04306900](https://ClinicalTrials.gov/show/NCT04306900) | TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers | Solid Tumor, Adult | TTX-030, budigalimab and mFOLFOX6 +/- TTX-030, budigalimab and docetaxel +/- TTX-030 and mFOLFOX6 +/- TTX-030 and budigalimab +/- TTX-030, budigalimab, nab-paclitaxel and gemcitabine +/- TTX-030 and pembrolizumab +/- TTX-030, nab-paclitaxel and gemcitabine +/- Budigalimab and mFOLFOX6 | Trishula Therapeutics, AbbVie | Phase 1 |
| [NCT05374226](https://ClinicalTrials.gov/show/NCT05374226) | A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas | Advanced Solid Tumors or Lymphomas | JS019 | Suzhou Kebo Ruijun | Phase 1 |
| [NCT05075564](https://ClinicalTrials.gov/show/NCT05075564) | A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | Advanced Solid Tumor | Part 1 ES002023 +/- Part 2 ES002023 | Elpiscience | Phase 1 |
| [NCT05381935](https://ClinicalTrials.gov/show/NCT05381935) | A Study of ES014 (Anti-CD39/TGF-Î² Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | Advanced Solid Tumor | ES014 | Elpiscience | Phase 1 |
| [NCT05508373](https://ClinicalTrials.gov/show/NCT05508373) | A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | JS019 | Suzhou Kebo Ruijun | Phase 1 |
| [NCT03884556](https://ClinicalTrials.gov/show/NCT03884556) | TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | Solid Tumor|Lymphoma | TTX-030 +/- Pembrolizumab +/- Gemcitabine +/- nab paclitaxel | Trishula | Phase 1 |
| **NCT** | **Project title** | **Conditions** | **Interventions** | **Sponsor** | **Phases** |
| [NCT04336098](https://ClinicalTrials.gov/show/NCT04336098) | Study of SRF617 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | SRF617 +/- Gemcitabine +/- Albumin-Bound Paclitaxel +/- Pembrolizumab | Surface Oncology  Merck Sharp & Dohme | Phase 1 |
| [NCT05177770](https://ClinicalTrials.gov/show/NCT05177770) | Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | SRF617 +/- etrumadenant +/- zimberelimab | Surface Oncology  Arcus Biosciences | Phase 2 |